Rakuten Medical is the lead sponsor of 4 current clinical trials in our USA, India, China and EU (CTIS) registers. 1 is recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Pembrolizumab, Carboplatin and Paclitaxel. The most-studied condition is Recurrent Head and Neck Squamous Cell Carcinoma.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
NCT06699212 · ClinicalTrials.gov ↗ · Recurrent Head and Neck Squamous Cell Carcinoma
|
Phase 3 | Recruiting | 2024-12 | USA, China |
|
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
NCT03769506 · ClinicalTrials.gov ↗ · Head and Neck Cancer
|
Phase 3 | Active, closed | 2019-05 | USA, India |
|
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
NCT04305795 · ClinicalTrials.gov ↗ · Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma
Drugs: Cemiplimab, Pembrolizumab |
Phase 1/2 | Active, closed | 2020-12 | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System with Rakuten Medical as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 3 | 1 |
| Clinical trials in India | 1 | 0 |
| Clinical trials in China | 1 | 1 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers.
| Sponsor | Trials |
|---|---|
| Bicara Therapeutics | 2 |
Sponsors with the most current trials registered for this condition.
Rakuten Medical is the lead sponsor of 3 current trials on ClinicalTrials.gov in our USA, India and China registers, and 1 authorised or ongoing trial in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of its 3 ClinicalTrials.gov trials is recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 7 drugs and biologicals as interventions. The most frequent are Pembrolizumab (3), Carboplatin (2), Paclitaxel (2), Cemiplimab (1) and Cisplatin (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.